Immatics N.V.(IMTX)Earnings, Financials & Key Ratios
IMTX•NASDAQ
$11.14
$1.49B mkt cap·67.7× P/E·Price updated May 7, 2026
AboutImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Show more
- Revenue$156M+188.6%
- EBITDA-$26M+72.1%
- Net Income$15M+115.7%
- EPS (Diluted)0.14+111.7%
- Gross Margin100%+183.5%
- EBITDA Margin-16.93%+90.3%
- Operating Margin-24.78%+86.8%
- Net Margin9.77%+105.4%
- ROE3.8%+108.6%
- ROIC-15.39%+89.8%
- Debt/Equity0.03-58.8%
- Interest Coverage-43.58+64.4%
IMTX Key Insights
Immatics N.V. (IMTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 53.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 32.6% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IMTX Price & Volume
Immatics N.V. (IMTX) stock price & volume — 10-year historical chart
Loading chart...
IMTX Growth Metrics
Immatics N.V. (IMTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years53.23%
3 Years64.89%
TTM-26.73%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-107.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-40.07%
Return on Capital
10 Years-43.76%
5 Years-28.03%
3 Years-7.74%
Last Year-7.87%
IMTX Recent Earnings
Immatics N.V. (IMTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Mar 5, 2026EPS
$0.34
Est $0.48
+29.2%
Revenue
$22M
Est $11M
+98.2%
Q4 2025
Nov 17, 2025EPS
$0.49
Est $0.44
-11.5%
Revenue
$6M
Est $11M
-43.3%
Q3 2025
Aug 13, 2025EPS
$0.66
Est $0.38
-73.7%
Revenue
$6M
Est $13M
-55.5%
Q2 2025
May 13, 2025EPS
$0.35
Est $0.39
+10.3%
Revenue
$20M
Est $14M
+50.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.34vs $0.48+29.2% | $22Mvs $11M+98.2% |
| Q4 2025 | Nov 17, 2025 | $0.49vs $0.44-11.5% | $6Mvs $11M-43.3% |
| Q3 2025 | Aug 13, 2025 | $0.66vs $0.38-73.7% | $6Mvs $13M-55.5% |
| Q2 2025 | May 13, 2025 | $0.35vs $0.39+10.3% | $20Mvs $14M+50.8% |
Based on last 12 quarters of dataView full earnings history →
IMTX Peer Comparison
Immatics N.V. (IMTX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TCRT | 5.82M | 2.67 | -0.91 | 100% | -670.83% | -167.97% | ||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRIS | 75.96M | 0.58 | -0.99 | -13.43% | -80.29% | -138.81% | 0.30 | |
 NKTX | 222.53M | 3.15 | -1.97 | -30.37% | 0.20 | |||
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 |
Compare IMTX vs Peers
Immatics N.V. (IMTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMTX Income Statement
Immatics N.V. (IMTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.77M | 18.45M | 31.25M | 34.76M | 172.83M | 54M | 155.84M | 84.76M |
| Revenue Growth % | - | 389.36% | 69.4% | 11.23% | 397.17% | -68.76% | 188.6% | -26.73% |
| Cost of Goods Sold | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 0 | 0 |
| COGS % of Revenue | 901.09% | 217.31% | 214.65% | 251.92% | 61.78% | 219.76% | - | - |
| Gross Profit | -30.2M▲ 0% | -21.64M▲ 28.3% | -35.83M▼ 65.6% | -52.81M▼ 47.4% | 66.05M▲ 225.1% | -64.67M▼ 197.9% | 155.84M▲ 341.0% | 84.76M▲ 0% |
| Gross Margin % | -801.09% | -117.31% | -114.65% | -151.92% | 38.22% | -119.76% | 100% | 100% |
| Gross Profit Growth % | - | 28.34% | -65.57% | -47.38% | 225.07% | -197.9% | 340.98% | - |
| Operating Expenses | 38.18M | 51.46M | 100.97M | 121.05M | 142.88M | 155.72M | 194.45M | 226.99M |
| OpEx % of Revenue | 1012.71% | 278.94% | 323.07% | 348.22% | 82.67% | 288.39% | 124.78% | - |
| Selling, General & Admin | 7.67M | 11.76M | 34.19M | 33.81M | 36.12M | 38.2M | 46.45M | 51.04M |
| SG&A % of Revenue | 203.34% | 63.72% | 109.38% | 97.25% | 20.9% | 70.74% | 29.81% | - |
| Research & Development | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 148.08M | 176.04M |
| R&D % of Revenue | 901.09% | 217.31% | 214.65% | 251.92% | 61.78% | 219.76% | 95.02% | - |
| Other Operating Expenses | -3.46M | -385K | -303K | -332K | -26K | -1.14M | -78K | -94K |
| Operating Income | -34.41M▲ 0% | -33.01M▲ 4.1% | -69.72M▼ 111.2% | -86.29M▼ 23.8% | 29.95M▲ 134.7% | -101.72M▼ 439.6% | -38.62M▲ 62.0% | -142.23M▲ 0% |
| Operating Margin % | -912.71% | -178.94% | -223.07% | -248.24% | 17.33% | -188.39% | -24.78% | -167.81% |
| Operating Income Growth % | - | 4.06% | -111.17% | -23.78% | 134.71% | -439.6% | 62.04% | - |
| EBITDA | -32.16M | -29.17M | -65.59M | -80.82M | 36.8M | -94.49M | -26.39M | -129.92M |
| EBITDA Margin % | -853.14% | -158.09% | -209.88% | -232.5% | 21.29% | -174.99% | -16.93% | -153.29% |
| EBITDA Growth % | - | 9.32% | -124.89% | -23.22% | 145.53% | -356.8% | 72.07% | -130.35% |
| D&A (Non-Cash Add-back) | 2.25M | 3.85M | 4.12M | 5.47M | 6.84M | 7.23M | 12.22M | 12.31M |
| EBIT | -32.34M | -32.32M | -211.55M | -92.77M | 43.07M | -96.16M | 22.23M | -118.64M |
| Net Interest Income | 491K | 620K | 561K | -433K | 1.44M | 13.01M | 24.11M | 19.49M |
| Interest Income | 507K | 790K | 850K | 133K | 2.48M | 13.85M | 25M | 20.45M |
| Interest Expense | 16K | 170K | 289K | 566K | 1.04M | 831K | 886K | 956K |
| Other Income/Expense | 2.05M | 526K | -142.13M | -7.04M | 12.08M | 4.73M | 59.96M | 22.63M |
| Pretax Income | -32.35M▲ 0% | -32.49M▼ 0.4% | -229.62M▼ 606.8% | -93.33M▲ 59.4% | 42.04M▲ 145.0% | -96.99M▼ 330.7% | 21.35M▲ 122.0% | -119.6M▲ 0% |
| Pretax Margin % | -858.22% | -176.09% | -734.7% | -268.49% | 24.32% | -179.63% | 13.7% | -141.11% |
| Income Tax | 0 | 0 | -268K | 0 | 4.55M | 0 | 6.13M | -3.71M |
| Effective Tax Rate % | 0% | 0% | 0.12% | 0% | 10.83% | 0% | 28.71% | 3.11% |
| Net Income | -31.44M▲ 0% | -31.74M▼ 0.9% | -229.35M▼ 622.6% | -95.06M▲ 58.6% | 37.51M▲ 139.5% | -96.99M▼ 358.6% | 15.22M▲ 115.7% | -115.89M▲ 0% |
| Net Margin % | -834.06% | -172.05% | -733.84% | -273.45% | 21.71% | -179.63% | 9.77% | -136.72% |
| Net Income Growth % | - | -0.94% | -622.56% | 58.55% | 139.46% | -358.55% | 115.69% | -107.63% |
| Net Income (Continuing) | -32.35M | -32.49M | -211.84M | -93.33M | 37.51M | -96.99M | 15.22M | -115.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.50▲ 0% | -0.50▲ 0.0% | -4.78▼ 856.0% | -1.51▲ 68.4% | 0.54▲ 135.8% | -1.20▼ 322.2% | 0.14▲ 111.7% | -0.95▲ 0% |
| EPS Growth % | - | 0% | -856% | 68.41% | 135.76% | -322.22% | 111.67% | -40.07% |
| EPS (Basic) | -0.50 | -0.50 | -4.78 | -1.51 | 0.55 | -1.20 | 0.14 | - |
| Diluted Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 68.82M | 80.55M | 106.8M | 121.56M |
| Basic Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 67.22M | 80.55M | 108.7M | 121.56M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IMTX Balance Sheet
Immatics N.V. (IMTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 55.29M | 124M | 238.99M | 152.21M | 377.15M | 449.37M | 629.55M | 458.02M |
| Cash & Short-Term Investments | 52.47M | 119.38M | 231.98M | 145.12M | 362.2M | 425.89M | 604.45M | 430.84M |
| Cash Only | 39.37M | 103.35M | 207.53M | 132.99M | 148.52M | 218.47M | 236.75M | 334.92M |
| Short-Term Investments | 13.1M | 16.02M | 24.45M | 12.12M | 213.69M | 207.42M | 367.7M | 95.92M |
| Accounts Receivable | 1.82M | 2.72M | 2.92M | 2.36M | 1.11M | 5.74M | 6.75M | 4.3M |
| Days Sales Outstanding | 176.01 | 53.87 | 34.14 | 24.77 | 2.35 | 38.78 | 15.8 | 22.11 |
| Inventory | 0 | 1.24M | 3.3M | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 11.25 | 17.97 | - | - | - | - | - |
| Other Current Assets | 1M | 665K | 1.7M | 950K | 13.84M | 7.12M | 6.31M | 9.18M |
| Total Non-Current Assets | 6.03M | 10.28M | 15.65M | 22.44M | 30.67M | 60.59M | 66.59M | 60.53M |
| Property, Plant & Equipment | 4.01M | 8.01M | 14.02M | 20.49M | 26.49M | 57.05M | 63.71M | 58.15M |
| Fixed Asset Turnover | 0.94x | 2.30x | 2.23x | 1.70x | 6.52x | 0.95x | 2.45x | 1.37x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.04M | 1.01M | 913K | 1.31M | 1.63M | 1.52M | 1.63M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 984K | 1.26M | 726K | 636K | 2.54M | 2.02M | 1.25M | 4.2M |
| Total Assets | 61.32M▲ 0% | 134.28M▲ 119.0% | 254.65M▲ 89.6% | 174.65M▼ 31.4% | 407.82M▲ 133.5% | 509.96M▲ 25.0% | 696.15M▲ 36.5% | 518.56M▲ 0% |
| Asset Turnover | 0.06x | 0.14x | 0.12x | 0.20x | 0.42x | 0.11x | 0.22x | 0.14x |
| Asset Growth % | - | 118.98% | 89.64% | -31.42% | 133.51% | 25.05% | 36.51% | 14.99% |
| Total Current Liabilities | 26.84M | 69.3M | 60.61M | 95.15M | 106.45M | 156.55M | 67.99M | 62.26M |
| Accounts Payable | 4.8M | 4.87M | 2.55M | 3.01M | 4.03M | 7.67M | 10.11M | 2.8M |
| Days Payables Outstanding | 51.6 | 44.3 | 13.9 | 12.54 | 13.76 | 23.58 | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 21.75M | 59.63M | 46.6M | 50.4M | 64.96M | 100.4M | 35.91M | 111.15M |
| Other Current Liabilities | 888K | 65K | 212K | 28.04M | 17.88M | 20.48M | 4.77M | 10.6M |
| Current Ratio | 2.06x | 1.79x | 3.94x | 1.60x | 3.54x | 2.87x | 9.26x | 9.26x |
| Quick Ratio | 2.06x | 1.77x | 3.89x | 1.60x | 3.54x | 2.87x | 9.26x | 9.26x |
| Cash Conversion Cycle | - | 20.82 | 38.21 | - | - | - | - | 22.11 |
| Total Non-Current Liabilities | 43.65M | 105.82M | 89.78M | 55.44M | 88.2M | 128.33M | 53.32M | 39.62M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 1.82M | 4.31M | 7.14M | 12.4M | 12.8M | 13.35M | 56.3M |
| Deferred Tax Liabilities | 0 | 0 | -4.31M | 0 | 0 | 0 | 5.8M | 18.1M |
| Other Non-Current Liabilities | 220K | 103.99M | 0 | 48.29M | 42K | 115.53M | 0 | 0 |
| Total Liabilities | 70.49M | 175.11M | 150.39M | 150.58M | 194.66M | 284.88M | 121.3M | 101.88M |
| Total Debt | 0 | 3.23M | 6.19M | 9.85M | 14.56M | 15.4M | 16.2M | 16.38M |
| Net Debt | -39.37M | -100.12M | -201.34M | -123.14M | -133.96M | -203.07M | -220.54M | -318.54M |
| Debt / Equity | - | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | 0.40x | - | - | -0.13x |
| Net Debt / EBITDA | - | - | - | - | -3.64x | - | - | 2.45x |
| Interest Coverage | -2150.56x | -194.19x | -241.23x | -152.46x | 28.86x | -122.41x | -43.58x | -124.10x |
| Total Equity | -9.17M▲ 0% | -40.84M▼ 345.3% | 104.26M▲ 355.3% | 24.06M▼ 76.9% | 213.16M▲ 785.9% | 225.08M▲ 5.6% | 574.84M▲ 155.4% | 416.68M▲ 0% |
| Equity Growth % | - | -345.26% | 355.31% | -76.92% | 785.86% | 5.59% | 155.39% | 217.85% |
| Book Value per Share | -0.15 | -0.65 | 2.17 | 0.38 | 3.10 | 2.79 | 5.38 | 3.43 |
| Total Shareholders' Equity | -10.41M | -41.85M | 104.26M | 24.06M | 213.16M | 225.08M | 574.84M | 416.68M |
| Common Stock | 1.16M | 1.16M | 629K | 629K | 767K | 847K | 1.22M | 1.22M |
| Retained Earnings | -201.62M | -233.19M | -462.25M | -537.81M | -500.3M | -597.29M | -589.54M | -750.29M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -741K | -770K | -7.46M | -3.94M | -1.48M | -1.64M | 1.03M | -8.11M |
| Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 |
IMTX Cash Flow Statement
Immatics N.V. (IMTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 20.68M | 70.97M | -85.61M | -81.78M | 100.13M | 18.23M | -158.03M | -158.03M |
| Operating CF Margin % | 548.65% | 384.67% | -273.93% | -235.26% | 57.94% | 33.76% | -101.41% | - |
| Operating CF Growth % | - | 243.1% | -220.63% | 4.47% | 222.43% | -81.8% | -966.96% | -228.95% |
| Net Income | -32.35M | -32.49M | -229.62M | -93.33M | 37.51M | -94.65M | 15.22M | -115.89M |
| Depreciation & Amortization | 2.18M | 3.86M | 4.42M | 5.26M | 6.97M | 7.23M | 12.22M | 12.31M |
| Stock-Based Compensation | 1.48M | 852K | 22.95M | 26.4M | 22.57M | 20.7M | 17.64M | 16.24M |
| Deferred Taxes | 491K | 623K | -3.96M | 11.15M | 4.52M | 0 | 6.13M | -3.59M |
| Other Non-Cash Items | -271K | 1.24M | 145.87M | 433K | -8.7M | 3.31M | -45.37M | 1.82M |
| Working Capital Changes | 49.16M | 96.88M | -25.28M | -31.7M | 37.26M | 81.63M | -163.88M | -85.21M |
| Change in Receivables | -175K | -563K | -294K | 569K | -429K | -2.98M | -1.76M | -248K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -84.24M | 0 | 0 |
| Change in Payables | 43.73M | 98.94M | -23.39M | -31.78M | 45.56M | 84.24M | 0 | 0 |
| Cash from Investing | -13.51M | -5.06M | -15.95M | 7.49M | -209.79M | -31.39M | -152.39M | 186.3M |
| Capital Expenditures | -507K | -2.23M | -7.52M | -5.66M | -6.21M | -30.8M | -16.27M | -7.26M |
| CapEx % of Revenue | 13.45% | 12.11% | 24.07% | 16.27% | 3.6% | 57.04% | 10.44% | - |
| Acquisitions | 97.01K | 91K | 104K | 551K | -199.91M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 94K | 6K | -104K | -551K | 199.96M | -8K | -206K | -202K |
| Cash from Financing | 23.65M | -1.86M | 207.88M | -2.61M | 123.71M | 84.52M | 319.68M | 144.16M |
| Debt Issued (Net) | 0 | -1.86M | -2.1M | -2.71M | -2.84M | -3.85M | -2.01M | -3M |
| Equity Issued (Net) | 1000K | 0 | 1000K | 94K | 1000K | 1000K | 1000K | 1.01M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -7.94M | 0 | -7.93M | -2.04M | -21.31M | -21.31M |
| Net Change in Cash | 30.95M▲ 0% | 63.99M▲ 106.7% | 104.18M▲ 62.8% | -74.54M▼ 171.5% | 15.53M▲ 120.8% | 69.95M▲ 350.6% | 18.28M▼ 73.9% | 145.72M▲ 0% |
| Free Cash Flow | 20.18M▲ 0% | 68.73M▲ 240.7% | -93.13M▼ 235.5% | -87.44M▲ 6.1% | 93.92M▲ 207.4% | -12.73M▼ 113.6% | -174.51M▼ 1271.0% | -183.95M▲ 0% |
| FCF Margin % | 535.2% | 372.56% | -298% | -251.53% | 54.34% | -23.57% | -111.98% | -217.03% |
| FCF Growth % | - | 240.65% | -235.5% | 6.11% | 207.41% | -113.55% | -1270.96% | -310.95% |
| FCF per Share | 0.32 | 1.09 | -1.94 | -1.39 | 1.36 | -0.16 | -1.63 | -1.63 |
| FCF Conversion (FCF/Net Income) | -0.66x | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x | 1.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMTX Key Ratios
Immatics N.V. (IMTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -723.26% | -148.16% | 31.63% | -44.26% | 3.8% | -27.81% |
| Return on Invested Capital (ROIC) | - | - | - | 28.36% | -150.75% | -15.39% | -15.39% |
| Gross Margin | -117.31% | -114.65% | -151.92% | 38.22% | -119.76% | 100% | 100% |
| Net Margin | -172.05% | -733.84% | -273.45% | 21.71% | -179.63% | 9.77% | -136.72% |
| Debt / Equity | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x | 0.03x |
| Interest Coverage | -194.19x | -241.23x | -152.46x | 28.86x | -122.41x | -43.58x | -124.10x |
| FCF Conversion | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x | 1.59x |
| Revenue Growth | 389.36% | 69.4% | 11.23% | 397.17% | -68.76% | 188.6% | -26.73% |
IMTX Frequently Asked Questions
Immatics N.V. (IMTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immatics N.V. (IMTX) reported $84.8M in revenue for fiscal year 2024. This represents a 2148% increase from $3.8M in 2018.
Immatics N.V. (IMTX) grew revenue by 188.6% over the past year. This is strong growth.
Immatics N.V. (IMTX) reported a net loss of $115.9M for fiscal year 2024.
Dividend & Returns
Immatics N.V. (IMTX) has a return on equity (ROE) of 3.8%. This is below average, suggesting room for improvement.
Immatics N.V. (IMTX) had negative free cash flow of $183.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More IMTX
Immatics N.V. (IMTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates